Since making the split from AbbVie (Nasdaq:ABBV), Abbott Labs (NYSE:ABT) has had something of a mixed debut. The stock has not only lagged AbbVie to a meaningful degree this year, but also other med-tech stocks like Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ). While some of this can be tied to concerns about the infant nutrition business, the fact remains that the new Abbott isn't as high-growth or high-margin as some investors want to believe, and management has their work cut out to improve performance. I do like the company's recent M&A moves to bulk up the device business, but this doesn't look like a particularly cheap stock today.
 
Decent Q2 Earnings With Improving Margins
One of the big items on the Abbott Labs to-do list is to drive better margins, and the company certainly made some progress this quarter. Even so, lower-than-expected growth in emerging markets is likely to linger as a concern, and the company's device business is looking quite soft at the moment.
 
Overall revenue rose more than 2% as reported, or about 4% on a constant currency basis, missing estimates slightly. Nutrition led the way in terms of growth (up more than 8% cc) and absolute dollars (31% of the total), but still missed the sell-side target by about 2%. OUS growth was a robust 17%, but slowdowns in emerging markets are a bit of a concern for the industry. 

SEE: Strategies For Quarterly Earnings Season

Abbott's other business were more mediocre. Diagnostics revenue was up almost 8%, but device revenue was virtually flat and branded generics (“Established Pharmaceuticals) revenue was down 2% as reported and barely up in constant currency terms.
 
Margins were more positive. Gross margin declined almost a point from the year-ago level, but were still about a half-point higher than expected. Likewise, adjusted operating income was only up about 4%, but the operating margin was about 30bp better than expected and the SG&A/revenue ratio declined 70bp from last year.
 
No Joy In Devices, And Probably Not Much On The Way Immediately
Given the earnings we've seen so far (and analyst expectations for those who haven't reported), Abbott's weak results in devices aren't a big surprise. Even so, barely positive revenue in vascular probably won't improve immediately, and the company is looking at serious, sustained competitive pressures from the likes of Medtronic and Boston Scientific (NYSE: BSX) in drug-eluting stents, Medtronic, BSX, JNJ, Covidien (NYSE:COV), and Bard (NYSE:BCR) in peripheral, and many of the above in structural heart.
 
Diabetes was more mixed. The slight decline in revenue was unimpressive on its own, but quite good compared to the significant decline at JNJ and the declines expected at Roche (Nasdaq:RHHBY) as Medicare changes its reimbursement policies for glucose testing.
 
Building A Better Business Will Take Time
Abbott has a very good nutrition business which, along with Mead Johnson (NYSE:MJN) dominates the U.S. market for infant and adult nutrition. The company is also looking to gain share in China, a huge market that is likely to account for more than half of global growth in the next five years. While China is already cracking down on the high price of formula in the country (and Abbott has already responded with a price cut), and companies like Mead Johnson, Nestle (Nasdaq:NSRGY), and Danone (Nasdaq:DANOY) are serious competitors, I like Abbott's chances for share growth, not to mention the under-appreciated potential of adult nutrition (Ensure), which only recently launched in China.
 
There's work to do elsewhere, though. The company recently made two promising acquisitions in the peripheral vascular and vision care spaces, but I think the company could use some additional growth-oriented business platforms. Along similar lines, Abbott could really stand to beef up its automation capabilities in the diagnostics space. It's also important for the company to improve margins, as the overall margin picture isn't all that great relative to its peer group.
 
The Bottom Line
I'm not as enamored with Abbott as some investors, but that's largely tied to what I see as incomplete platforms in devices and diagnostics that are likely going to require further M&A and/or management attention. The nutrition business will patch over a lot of holes, though, and the EPD business should be a good business on balance.
 
Even with an expectation of mid-teens free cash flow growth over the next decade, Abbott shares don't look like a particular bargain. There's certainly upside if Abbott's emerging market nutrition business grows faster than expected and/or if the device business improves its growth and/or margins faster than I expect. As is, though, I think $36 to $37 is a pretty fair price for the stock.

Disclosure - As of this writing, the author owns shares of Roche.
 

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Stock Analysis

    5 Reasons Thoratec Corp. Keeps Impressing Investors

    Learn about Thoratec Corporation and its position in its industry. Understand five key factors why the company has impressed investors.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!